Jan. 5, 2012
/PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in
January 8 through 13
Representatives of Antigen Express will be available over the course of the conference to meet with prospective partners, collaborators, and investors in respect of the Antigen Express proprietary platform immunotherapeutic vaccine technologies.
, Generex President & Chief Executive Officer, has commented: "In particular, the recently announced positive interim clinical data from our Phase 2b study in HER-2 expressing breast cancer subjects makes the time ripe for discussions with prospective partners and collaborations in respect of a Phase 3 study of the breast cancer vaccine."
"Several distinct products are being developed with the Antigen Express Ii-Key technology and are at various stages of development," said
of Seahawk Capital Partners, Inc. "The JPMorgan Healthcare Conference gives Antigen Express the opportunity to initiate discussions with multiple interested partners. The different products have applicability in diseases such as breast cancer, prostate cancer, ovarian cancer, influenza, and HIV. Recent interim data suggesting efficacy of one product, cancer vaccine AE-37 (Ii-Key/HER2 antigen hybrid), has helped to validate the Ii-Key antigen technology overall." Mr. Moscato went on to say: "The Ii-Key Hybrid technology allows tumor-associated or foreign antigens (like viral antigens) to potently enhance the immune system's ability to recognize and destroy cancerous or virus infected cells bearing any of the targeted antigens as well as generate immunological memory. We are committed to finding alliances and partners to work together on the best clinical trial program for each distinct product."
Interested parties are invited to contact:Mr.
Seahawk Capital Partners, Inc.646-599-6222
About AE37 and Ii-Key Hybrid Platform Technology
Antigen Express is a platform technology and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells. Incorporating the Ii-Key modification along with tumor-associated antigens can greatly enhance the immune system's ability to recognize and destroy cancer cells bearing any of the targeted antigens as well as increasing immunological memory.